Neuropace Inc (NPCE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuropace Inc (NPCE) has a cash flow conversion efficiency ratio of -0.328x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.90 Million) by net assets ($11.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NPCE market cap for the company's overall valuation and market capitalisation.
Neuropace Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Neuropace Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neuropace Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuropace Inc ranked by their cash flow conversion efficiency. See Neuropace Inc (NPCE) cash flow to debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Yuanlong Yato Culture Dissemination Co Ltd
SHE:002878
|
-0.096x |
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SHE:002395
|
0.024x |
|
Compania General de Electricidad SA
SN:CGE
|
-0.004x |
|
Shenzhen Jiawei Photovoltaic Lighting Co Ltd
SHE:300317
|
0.015x |
|
Hunan Lead Power Dazhi Technology Inc Co
SHE:300530
|
-0.195x |
|
Weebit Nano Ltd
AU:WBT
|
-0.109x |
|
Abaxx Technologies Inc
NEO:ABXX
|
-0.245x |
|
Zhejiang Sunrise Garment Group Co Ltd
SHG:605138
|
N/A |
Annual Cash Flow Conversion Efficiency for Neuropace Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neuropace Inc from 2019 to 2025. View current stock price of Neuropace Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $19.03 Million | $-11.01 Million | -0.578x | +74.18% |
| 2024-12-31 | $8.01 Million | $-17.95 Million | -2.240x | -134.83% |
| 2023-12-31 | $20.65 Million | $-19.70 Million | -0.954x | +10.03% |
| 2022-12-31 | $34.78 Million | $-36.87 Million | -1.060x | -217.06% |
| 2021-12-31 | $73.50 Million | $-24.58 Million | -0.334x | -328.75% |
| 2020-12-31 | $-147.83 Million | $-21.61 Million | 0.146x | -24.45% |
| 2019-12-31 | $-129.35 Million | $-25.03 Million | 0.193x | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more